Adaptimmune Therapeutics CEO James Noble's 2018 pay jumps 58% to $2.6M
Adaptimmune Therapeutics reports 2018 executive compensation
By ExecPay News
Published: March 15, 2019
Adaptimmune Therapeutics reported fiscal year 2018 executive compensation information on March 15, 2019.
In 2018, five executives at Adaptimmune Therapeutics received on average a compensation package of $1.8M, a 13% increase compared to previous year.
Average pay of disclosed executives at Adaptimmune Therapeutics
James Noble, Chief Executive Officer, received $2.6M in total, which increased by 58% compared to 2017. 69% of Noble's compensation, or $1.8M, was in option awards. Noble also received $251K in non-equity incentive plan, $536K in salary, as well as $28K in other compensation.
For fiscal year 2018, the median employee pay was $137,800 at Adaptimmune Therapeutics. Therefore, the ratio of James Noble's pay to the median employee pay was 19 to one.
Rafael Amado, President, Research & Development, received a compensation package of $2.6M, which increased by 69% compared to previous year. 73% of the compensation package, or $1.9M, was in option awards.
Adrian Rawcliffe, Chief Financial Officer, earned $1.4M in 2018, a 8% decrease compared to previous year.
William Bertrand, Chief Operating Officer, received $1.3M in 2018, which decreases by 35% compared to 2017.
Helen Tayton-Martin, Chief Business Officer, earned $1.3M in 2018, a 8% decrease compared to previous year.
Related executives
James Noble
Adaptimmune Therapeutics
Chief Executive Officer
Adrian Rawcliffe
Adaptimmune Therapeutics
Chief Executive Officer
Rafael Amado
Adaptimmune Therapeutics
President, Research & Development
Helen Tayton-Martin
Adaptimmune Therapeutics
Chief Business Officer
William Bertrand
Adaptimmune Therapeutics
Chief Operating Officer
You may also like
Source: SEC filing on March 15, 2019.